2007DOAJ (DOAJ: Directory of Open Access Journals)Open access

Relationship Between Post-transplant Lymphoproliferative Disorder and Anti-Thymocyte Globulin or Anti-Lymphocyte Globulin

Kh. Rahbar, E. Ghanei, A. Nasrollahi, M Homayouni

Open full text 0 citations

Abstract

Background:Lymphoproliferative disorders are among the most serious and potentially fatal complications of chronic immunosuppression in kidney transplant recipients.The principle risk factors for development of PTLD are the degree of overall immunosuppression and the EBV serostatus of the recipient.In this study,the risk of PTLD in kidney transplant recipients who received Anti- Lymphocyte Globulin (ALG) or Anti Thymocyte Globulin (ATG) was evaluated.Methods:We retrospectively studied 520 patients who underwent kidney transplantation during the period from December 1989 to December 2002,at Taleghani Hospital, Tehran. Results:369 patients received classic immunosuppression (prednisolone,cyclosporine,mycophenolate mofetil) and 151 patients (29%) received classic immunosuppression with ALG or ATG.Eight patients had developed PTLD, 5 cases of which (62.5%) received classic immunosuppression without ALG or ATG. Incidence of PTLD was 3.3 percent in patients who received ALG or ATG and 0.8 percent for those patients who did not receive ATG or ALG. This difference is very significant (p < 0.05).Conclusion:ALG or ATG therapy could act as a risk factor for PTLD.

About this research paper

What this paper is about

Background:Lymphoproliferative disorders are among the most serious and potentially fatal complications of chronic immunosuppression in kidney transplant recipients.The principle risk factors for development of PTLD are the degree of overall immunosuppression and the EBV serostatus of the recipient.In this study,the risk of PTLD in kidney transplant recipients who received Anti- Lymphocyte Globulin (ALG) or Anti Thymocyte Globulin (ATG) was evaluated.Methods:We retrospectively studied 520 patients who underwent kidney transplantation during the period from December 1989 to December 2002,at Taleghani Hospital, Tehran. Results:369 patients received classic immunosuppression (prednisolone,cyclosporine,mycophenolate mofetil) and 151 patients (29%) received classic immunosuppression with ALG or ATG.Eight patients had developed PTLD, 5 cases of which (62.5%) received classic immunosuppression without ALG or ATG. Incidence of PTLD was 3.3 percent in patients who received ALG or ATG and 0.8 percent for those patients who did not receive ATG or ALG. This difference is very significant (p < 0.05).Conclusion:ALG or ATG therapy could act as a risk factor for PTLD.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Background:Lymphoproliferative disorders are among the most serious and potentially fatal complications of chronic immunosuppression in kidney transplant recipients.The principle risk factors for development of PTLD are the degree of overall immunosuppression and the EBV serostatus of the recipient.In this study,the risk of PTLD in kidney transplant recipients who received Anti- Lymphocyte Globulin (ALG) or Anti Thymocyte Globulin (ATG) was evaluated.Methods:We retrospectively studied 520 patients who underwent kidney transplantation during the period from December 1989 to December 2002,at Taleghani Hospital, Tehran. Results:369 patients received classic immunosuppression (prednisolone,cyclosporine,mycophenolate mofetil) and 151 patients (29%) received classic immunosuppression with ALG or ATG.Eight patients had developed PTLD, 5 cases of which (62.5%) received classic immunosuppression without ALG or ATG. Incidence of PTLD was 3.3 percent in patients who received ALG or ATG and 0.8 percent for those patients who did not receive ATG or ALG. This difference is very significant (p < 0.05).Conclusion:ALG or ATG therapy could act as a risk factor for PTLD.

Key concepts: Anti-thymocyte globulin, Globulin, Immunology, Post-transplant lymphoproliferative disorder, Thymocyte, Lymphoproliferative disorders, Lymphocyte, Biology

Related papers

Back to paper searchBrowse research topicsOriginal source
Relationship Between Post-transplant Lymphoproliferative Disorder and Anti-Thymocyte Globulin or Anti-Lymphocyte Globulin — Research Paper | ScholarLens